PL200679B1 - Preparat farmaceutyczny zolmitryptanu i zastosowanie zolmitryptanu - Google Patents

Preparat farmaceutyczny zolmitryptanu i zastosowanie zolmitryptanu

Info

Publication number: PL200679B1
Authority: PL; Poland
Prior art keywords: zolmitriptan; preparation; pharmaceutical; migraine; formulation
Prior art date: 1999-12-03

Application number

PL357597A

Other languages

English (en)

Polish (pl)

Other versions

PL357597A1 (en

Inventor

Alan Roy Dearn

Sarah Louise Williamson

Simon John Summers

Trevor John Coomber

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-03

Filing date

2000-11-28

Publication date

2009-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL200679(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-11-28 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-07-26 Publication of PL357597A1 publication Critical patent/PL357597A1/xx

2009-01-30 Publication of PL200679B1 publication Critical patent/PL200679B1/pl

Links

229960001360 zolmitriptan Drugs 0.000 title claims abstract description 43
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract description 43
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 19
238000002360 preparation method Methods 0.000 claims abstract description 13
239000003937 drug carrier Substances 0.000 claims abstract description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 21
238000000034 method Methods 0.000 claims description 11
239000001488 sodium phosphate Substances 0.000 claims description 7
239000007853 buffer solution Substances 0.000 claims description 6
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
229910000397 disodium phosphate Inorganic materials 0.000 claims description 6
235000019800 disodium phosphate Nutrition 0.000 claims description 6
239000000872 buffer Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 abstract description 16
206010027599 migraine Diseases 0.000 abstract description 16
238000011282 treatment Methods 0.000 abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract 1
238000009472 formulation Methods 0.000 description 17
239000000243 solution Substances 0.000 description 11
229960004106 citric acid Drugs 0.000 description 8
239000007922 nasal spray Substances 0.000 description 7
229940097496 nasal spray Drugs 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
102000035038 5-HT1 receptors Human genes 0.000 description 3
108091005478 5-HT1 receptors Proteins 0.000 description 3
206010019233 Headaches Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
-1 as dodecahydrate Chemical compound 0.000 description 3
DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
229960004543 anhydrous citric acid Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229920005556 chlorobutyl Polymers 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000007794 irritation Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
208000018912 cluster headache syndrome Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
150000004688 heptahydrates Chemical class 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960005254 naratriptan Drugs 0.000 description 1
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
238000011328 necessary treatment Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000009516 primary packaging Methods 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
229960000425 rizatriptan Drugs 0.000 description 1
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960003708 sumatriptan Drugs 0.000 description 1
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL357597A 1999-12-03 2000-11-28 Preparat farmaceutyczny zolmitryptanu i zastosowanie zolmitryptanu PL200679B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9928578.5A GB9928578D0 (en)	1999-12-03	1999-12-03	Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en)	1999-12-03	2000-11-28	Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number	Publication Date
PL357597A1 PL357597A1 (en)	2004-07-26
PL200679B1 true PL200679B1 (pl)	2009-01-30

Family

ID=10865629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL357597A PL200679B1 (pl)	1999-12-03	2000-11-28	Preparat farmaceutyczny zolmitryptanu i zastosowanie zolmitryptanu

Country Status (28)

Country	Link
US (2)	US6750237B1 (cs)
EP (1)	EP1237551B1 (cs)
JP (1)	JP2003515559A (cs)
KR (1)	KR100670092B1 (cs)
CN (1)	CN1222287C (cs)
AT (1)	ATE291914T1 (cs)
AU (1)	AU778092B2 (cs)
BR (1)	BRPI0016138B8 (cs)
CA (1)	CA2392050C (cs)
CZ (1)	CZ301528B6 (cs)
DE (1)	DE60019162T2 (cs)
EE (1)	EE05305B1 (cs)
ES (1)	ES2236001T3 (cs)
GB (2)	GB9928578D0 (cs)
HK (2)	HK1048442B (cs)
HU (1)	HU229458B1 (cs)
IL (2)	IL149578A0 (cs)
IS (1)	IS2135B (cs)
MX (1)	MXPA02005319A (cs)
NO (1)	NO322119B1 (cs)
NZ (1)	NZ518862A (cs)
PL (1)	PL200679B1 (cs)
PT (1)	PT1237551E (cs)
RU (1)	RU2255736C2 (cs)
SK (1)	SK287228B6 (cs)
UA (1)	UA75059C2 (cs)
WO (1)	WO2001039772A1 (cs)
ZA (1)	ZA200203704B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8465468B1 (en)	2000-06-29	2013-06-18	Becton, Dickinson And Company	Intradermal delivery of substances
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations
SE0102855D0 (sv) *	2001-08-27	2001-08-27	Astrazeneca Ab	Method of treatment
WO2005115360A2 (en) *	2004-05-11	2005-12-08	Becton, Dickinson And Company	Formulations of anti-pain agents and methods of using the same
EP3216445A1 (en) *	2004-05-28	2017-09-13	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
US8216610B2 (en)	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
EP1812428A2 (en) *	2004-11-19	2007-08-01	Teva Pharmaceutical Industries Ltd	Zolmitriptan crystal forms
CN100341504C (zh) *	2004-12-01	2007-10-10	鲁南制药集团股份有限公司	佐米曲普坦速释制剂
EP3263117A1 (en) *	2005-11-28	2018-01-03	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
WO2008016678A2 (en) *	2006-08-01	2008-02-07	Sunesis Pharmaceuticals, Inc.	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
WO2008049116A2 (en) *	2006-10-19	2008-04-24	Auspex Pharmaceuticals, Inc.	Substituted indoles
KR101517415B1 (ko) *	2008-05-14	2015-05-07	에스케이바이오팜 주식회사	난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
CN103402514B (zh)	2010-10-15	2016-01-13	康特拉医药公司	用于治疗运动障碍的血清素受体激动剂组合物
JP6121734B2 (ja) *	2012-02-09	2017-04-26	久光製薬株式会社	マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
MY169068A (en)	2012-04-18	2019-02-12	Contera Pharma Aps	Orally available pharmaceutical formulation suitable for improved management of movement disorders
US11554229B2 (en)	2013-03-26	2023-01-17	OptiNose Inc.	Nasal administration
KR101624049B1 (ko)	2014-10-29	2016-05-24	연세대학교 산학협력단	사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (en) *	2015-06-19	2024-03-27	Beijing Artivila BioPharma Co. Ltd.	Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2017122161A1 (en)	2016-01-15	2017-07-20	Cadila Healthcare Limited	An intranasal composition comprising 5ht1b/1d receptor agonists
CN109689036B (zh)	2016-07-11	2026-06-19	康特拉医药股份有限公司	用于治疗早晨运动不能的脉冲药物输送系统
EP3727333A1 (en) *	2017-12-21	2020-10-28	Taiwan Liposome Company Ltd	Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en)	2020-04-15	2021-10-21	Farzana Shaheen	Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ288351B6 (en) *	1990-06-07	2001-05-16	Astrazeneca Ab	Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
GB9012672D0 (en) *	1990-06-07	1990-08-01	Wellcome Found	Therapeutic heterocyclic compounds
GB9516145D0 (en) *	1995-08-07	1995-10-04	Wellcome Found	Improved chemical synthesis
US6255502B1 (en) *	1996-07-11	2001-07-03	Farmarc Nederland B.V.	Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) *	1996-08-01	1998-02-11	Merck & Co Inc	Treatment of migraine
US6461591B1 (en) *	1997-02-05	2002-10-08	Jago Research Ag	Medical aerosol formulations
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations

1999
- 1999-12-03 GB GBGB9928578.5A patent/GB9928578D0/en not_active Ceased
2000
- 2000-11-28 DE DE60019162T patent/DE60019162T2/de not_active Expired - Lifetime
- 2000-11-28 NZ NZ518862A patent/NZ518862A/en not_active IP Right Cessation
- 2000-11-28 SK SK753-2002A patent/SK287228B6/sk not_active IP Right Cessation
- 2000-11-28 CA CA002392050A patent/CA2392050C/en not_active Expired - Lifetime
- 2000-11-28 GB GB0214845A patent/GB2373726B/en not_active Expired - Lifetime
- 2000-11-28 AT AT00979765T patent/ATE291914T1/de active
- 2000-11-28 PT PT00979765T patent/PT1237551E/pt unknown
- 2000-11-28 HK HK03100515.3A patent/HK1048442B/zh not_active IP Right Cessation
- 2000-11-28 EE EEP200200283A patent/EE05305B1/xx unknown
- 2000-11-28 CZ CZ20021901A patent/CZ301528B6/cs not_active IP Right Cessation
- 2000-11-28 HK HK03100621.4A patent/HK1048445B/en not_active IP Right Cessation
- 2000-11-28 US US10/129,773 patent/US6750237B1/en not_active Expired - Lifetime
- 2000-11-28 UA UA2002075443A patent/UA75059C2/uk unknown
- 2000-11-28 CN CNB008163820A patent/CN1222287C/zh not_active Expired - Lifetime
- 2000-11-28 KR KR1020027006849A patent/KR100670092B1/ko not_active Expired - Lifetime
- 2000-11-28 IL IL14957800A patent/IL149578A0/xx active IP Right Grant
- 2000-11-28 EP EP00979765A patent/EP1237551B1/en not_active Expired - Lifetime
- 2000-11-28 WO PCT/GB2000/004528 patent/WO2001039772A1/en not_active Ceased
- 2000-11-28 PL PL357597A patent/PL200679B1/pl unknown
- 2000-11-28 JP JP2001541504A patent/JP2003515559A/ja active Pending
- 2000-11-28 AU AU17157/01A patent/AU778092B2/en not_active Expired
- 2000-11-28 BR BRPI0016138A patent/BRPI0016138B8/pt not_active IP Right Cessation
- 2000-11-28 ES ES00979765T patent/ES2236001T3/es not_active Expired - Lifetime
- 2000-11-28 RU RU2002117649/15A patent/RU2255736C2/ru active
- 2000-11-28 HU HU0203597A patent/HU229458B1/hu unknown
2002
- 2002-05-09 IL IL149578A patent/IL149578A/en unknown
- 2002-05-09 ZA ZA200203704A patent/ZA200203704B/xx unknown
- 2002-05-24 IS IS6394A patent/IS2135B/xx unknown
- 2002-05-28 NO NO20022525A patent/NO322119B1/no not_active IP Right Cessation
- 2002-05-29 MX MXPA02005319A patent/MXPA02005319A/es active IP Right Grant
2004
- 2004-05-27 US US10/854,959 patent/US7220767B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ20021901A3 (cs)	2002-11-13
HU229458B1 (en)	2013-12-30
NO20022525L (no)	2002-05-28
RU2255736C2 (ru)	2005-07-10
US7220767B2 (en)	2007-05-22
IS2135B (is)	2006-08-15
EE05305B1 (et)	2010-06-15
CA2392050A1 (en)	2001-06-07
HUP0203597A2 (hu)	2003-02-28
HK1048442B (zh)	2005-05-13
HK1053430A1 (en)	2003-10-24
DE60019162D1 (de)	2005-05-04
ES2236001T3 (es)	2005-07-16
MXPA02005319A (es)	2002-12-06
SK287228B6 (sk)	2010-03-08
AU1715701A (en)	2001-06-12
NO322119B1 (no)	2006-08-14
BR0016138A (pt)	2002-08-06
DE60019162T2 (de)	2006-02-02
GB2373726B (en)	2004-10-20
CA2392050C (en)	2009-11-24
US6750237B1 (en)	2004-06-15
SK7532002A3 (en)	2002-12-03
PL357597A1 (en)	2004-07-26
UA75059C2 (uk)	2006-03-15
CN1222287C (zh)	2005-10-12
GB2373726A (en)	2002-10-02
PT1237551E (pt)	2005-07-29
BR0016138B1 (pt)	2013-09-10
HK1048442A1 (en)	2003-04-04
KR20020058051A (ko)	2002-07-12
HUP0203597A3 (en)	2005-07-28
EE200200283A (et)	2003-06-16
NO20022525D0 (no)	2002-05-28
ZA200203704B (en)	2003-10-29
HK1048445A1 (en)	2003-04-04
US20040214899A1 (en)	2004-10-28
RU2002117649A (ru)	2004-01-27
AU778092B2 (en)	2004-11-18
CZ301528B6 (cs)	2010-04-07
HK1048445B (en)	2005-08-26
EP1237551B1 (en)	2005-03-30
IL149578A0 (en)	2002-11-10
CN1402636A (zh)	2003-03-12
BRPI0016138B8 (pt)	2021-05-25
KR100670092B1 (ko)	2007-01-17
IS6394A (is)	2002-05-24
ATE291914T1 (de)	2005-04-15
EP1237551A1 (en)	2002-09-11
GB9928578D0 (en)	2000-02-02
NZ518862A (en)	2004-02-27
WO2001039772A1 (en)	2001-06-07
GB0214845D0 (en)	2002-08-07
JP2003515559A (ja)	2003-05-07
IL149578A (en)	2008-04-13

Publication	Publication Date	Title
AU778092B2 (en)	2004-11-18	Pharmaceutical formulations containing zolmitriptan
ES2626134T3 (es)	2017-07-24	Composiciones de bepotastina
ES2236189T3 (es)	2005-07-16	Nueva combinacion de antihistaminicos no sedativos que contienen sustancias que influyen en la accion del leucotrieno, para el tratamiento de la rinitis/conjuntivitis.
ES2255287T3 (es)	2006-06-16	Composiciones para el tratamiento de la leucemia linfocitica cronica.
UA59385C2 (uk)	2003-09-15	Інтраназальна композиція для лікування сексуальних розладів
CZ284605B6 (cs)	1999-01-13	Léčivý přípravek pro léčení závislosti na nikotinu
HUP0303877A2 (hu)	2004-03-29	Imidazotriazinon-tartalmú készítmények nazális alkalmazásra
PL175860B1 (pl)	1999-02-26	Preparat w postaci kropli do oczu i sposób wytwarzania preparatu w postaci kropli do oczu.
US20080319087A1 (en)	2008-12-25	Use of Ambroxol for the Treatment of Rhinovirus Infections
RU2492852C2 (ru)	2013-09-20	Галеновая форма для трансмукозально-буккального введения триптанов
EP3052194B1 (en)	2021-06-16	A veterinary method for inducing emesis
GB2114001A (en)	1983-08-17	Nasal pharmaceutical compositions
CA1197783A (en)	1985-12-10	Nasal pharmaceutical compositions
ES2265007T3 (es)	2007-02-01	Preparado de combinacion para la terapia de enfermedades inmunologicas.
HK1053430B (en)	2006-04-13	Pharmaceutical formulations containing zolmitriptan
EP1095655A2 (en)	2001-05-02	NK-1 receptor antagonists and eletriptan for the treatment of migraine